You are here: Industry Insights > SOTIO

News List

SOTIO Opens Office in Basel, Switzerland, to Accelerate Development of its Pipeline Products b3cnewswire
January 17, 2020
SOTIO, a biotechnology company owned by the PPF Group, announce the opening of offices of SOTIO Biotech AG at the Technology Park Basel, Switzerland.
PPF and SOTIO Invest $6.5 Million in MaveriX Oncology and its Lead Program MVX-5005 b3cnewswire
October 15, 2019
SOTIO, together with PPF, and MaveriX Oncology, Inc., announce the investment of PPF Group in MaveriX Oncology Inc., a private biotech company with a proprietary pipeline of targeted ...
PPF Expands its Investment in the Healthcare Sector Through Acquisition of Significant Stake in T Cell Therapy Company Autolus Therapeutics b3cnewswire
September 17, 2019
PPF announces the acquisition of a 19.2% stake in Autolus Therapeutics plc, a leader in next-generation T cell programming technologies. The shares were acquired in the market through NASDAQ.
SOTIO Initiates First-In-Human Clinical Trial with IL-15 Superagonist SO-C101 b3cnewswire
July 12, 2019
SOTIO and Cytune Pharma, members of the PPF Group, announce today the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15.
SOTIO’s DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer b3cnewswire
June 03, 2019
SOTIO’s DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer.
SOTIO acquires Cytune Pharma biospectrumasia
September 03, 2018
All Cytune projects will be developed as part of SOTIO’s pipeline.
SOTIO and PPF Complete Acquisition of Cytune Pharma b3cnewswire
August 31, 2018
SOTIO, a biotechnology company owned by the PPF Group, announces today the completion of the acquisition of Cytune Pharma by PPF.
SOTIO Starts Phase I/II Trial of DCVAC in Combination with ONCOS-102: The Targovax Adenovirus Based Immunotherapy b3cnewswire.
June 04, 2018
SOTIO, a biotechnology company owned by the PPF Group, announces today that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa

Previous page 1 2 Next page